Prime Medicine, Inc.
PRME
$1.39
$0.1512.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.14% | -27.64% | -44.56% | -48.86% | -62.64% |
| Total Depreciation and Amortization | 31.70% | 32.32% | 45.36% | 64.80% | 109.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.88% | 31.25% | 65.86% | 24.82% | 9.71% |
| Change in Net Operating Assets | 1,074.01% | 68.64% | -6.71% | -93.77% | 107.48% |
| Cash from Operations | 25.72% | -20.17% | -37.04% | -56.25% | -25.48% |
| Capital Expenditure | 16.39% | 37.23% | 33.91% | 44.84% | 45.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.11% | 380.23% | -1,218.38% | 104.57% | 188.50% |
| Cash from Investing | 265.86% | 269.57% | -121.82% | 93.76% | 139.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28,883.36% | 2.21% | -18.23% | -18.15% | -99.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 1,871.43% | 1,255.64% | -- | -- |
| Cash from Financing | 29,804.73% | 6.25% | -13.98% | -13.63% | -99.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 196.87% | 1,970.21% | -329.29% | -29.21% | -5,780.51% |